Bodenstedt Matthias's Form 4 filing
MoonLake Immunotherapeutics (MLTX) · filed Apr 10, 2026
- Accession no.
- 0001213900-26-042629
- Filed
- Apr 10, 2026
- Trade date
- Apr 9-10, 2026
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions. Open-market sales total $1.66M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Bodenstedt MatthiasCIK 0001920545 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 9, 2026 | Class A ordinary shares, par value $0.0001 per share | SSaleDisposed | −85,870 | $18.94F2 | −$1,626,377.8 | 1,190,435 | Direct | |
| Apr 10, 2026 | Class A ordinary shares, par value $0.0001 per share | SSaleDisposed | −1,925 | $19.51F3 | −$37,556.75 | 1,188,510 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $18.340 to $19.455. Upon request by the staff of the U.S. Securities and Exchange Commission (the "SEC"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $19.500 to $19.560. Upon request by the staff of the SEC, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.